Literature DB >> 32319878

Borderless collaboration is needed for COVID-19-A disease that knows no borders.

Kawthar Mohamed1,2, Eduardo Rodríguez-Román3,4, Farzaneh Rahmani5,6, Hongbo Zhang7,8, Mariya Ivanovska9,10, Sara A Makka11,12, Musa Joya13,14, Rangarirai Makuku1,15, Md Shahidul Islam16,17, Nesrine Radwan18,19, Laila Rahmah1,20, Rayan Goda21,22, Sunny O Abarikwu23,24, Mujtaba Shaw1,25, Samaneh Zoghi26,27, Sevan Irtsyan28,29, Irene Ling30,31, Orsolya Cseprekal32,33, Attig-Bahar Faten34,35, Esra Hazar Sayar36,37, Chagajeg Soloukey38,39, Giulia Grancini40,41, Nima Rezaei1,42.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32319878      PMCID: PMC7231663          DOI: 10.1017/ice.2020.162

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


× No keyword cloud information.
To the Editor—Coronavirus disease 2019 (COVID-19) has become a global concern among all citizens and governments. Several governments have decided to take drastic actions to combat the spread of the disease, including closure of air, maritime, and land borders as an extreme measures of isolation. However, such measures have not prevented the disease from spreading globally; COVID-19 has already spread to almost all countries and regions, and the World Health Organization (WHO) named it a pandemic on March 11, 2020.[1] For this reason, some countries have announced a so-called ‘lockdown.’ This protocol includes, but is not limited to, the closure of all nonessential businesses, the obligatory physical isolation of all citizens through quarantine, social distancing for those that do go out of their homes, and public campaigns to encourage both frequent hand washing and refraining from touching the face. Although these measures seems to be effective in ‘flattening the curve,’ they cannot be applied for a long because they have extreme economic consequences. Vivid examples of such detrimental economic consequences have occurred in Singapore and Hong Kong, where social distancing was applied meticulously. As soon as the measures were withdrawn, a second surge of the disease occurred.[2] So, what is the solution? International collaboration seems to be the best tool for curbing the spread of SARS-CoV-2. This virus first hit more wealthy countries where resources and facilities were available, but even these wealthy countries failed to control it. SARS-CoV-2 knows no borders; it has reached every populated region on earth without discrimination. As SARS-CoV-2 spreads to countries with little or no sanitation, low or no hygiene, and few or no hospitals, the conditions could become extreme and dreadful. The prevention of this pending disaster is the role of every country on earth because this pandemic has no borders. Multinational, united efforts are required to end this crisis, which became evident when SARS-CoV-2 spread regardless of border closures. If wealthy countries do not support poor countries in curbing this viral infection, SARS-CoV-2 will find its way back to their countries. In addition to the humanitarian goals of this collaboration, scientific collaboration is needed as well. The host’s immune system has an important role in the transmission of SARS-CoV-2.[3] Multiple severe cases within families also suggests a genetic predisposition to COVID-19.[4] Thus, international collaboration to better understand the disease pathophysiology of COVID-19 is needed. In developed countries, telemedicine provides the opportunity for patients to communicate with physicians remotely via computer.[5] However, such tools, as well as research, diagnostic kits, and vaccine manufacturers require a huge budget beyond a single country’s financial capability. This international collaboration should begin before SARS-CoV-2 spreads tragicallly through poor countries. This crisis is growing everywhere on our planet, and if we work together, we might find a solution. For example, a single poor country cannot afford to support test manufacturers. Now the crisis involves mostly rich countries, but what will happen when poor countries without adequate hygiene, sanitation, or well-equipped hospitals and facilities are affected? The consequences could be horrific, with an unimaginable toll. We should start supporting these poor countries before the virus explodes among them. To refuse to come to their aid is cruel and against humanitarian and moral values. Also, if SARS-CoV-2 spreads uncontrolled, it is more likely to re-emerge in wealthy countries.[6] The type of collaboration needed has happened before. The smallpox pandemic, a tragedy that killed ~2 million people in 1967, is one example. Nobody believed that the smallpox virus could be stopped, but eventually the goal was achieved, with an intense worldwide collaboration that took ~13 years (1967–1979). The smallpox eradication program was funded by the WHO and 42 other countries. The expense of this accomplishment was merely $112 million in total, or an average of $9 million per year over these 13 years. Some countries spent more individually to stop this pandemic, but their efforts were in vain.[7] The global effort now needed to stop the COVID-19 pandemic should not be as difficult because of the internet as well as nongovernmental organizations such as the Universal Scientific and Educational Network (USERN), which connects scientists and students from >100 different countries.[8] In conclusion, we may be wasting important time; a borderless solution for our complex COVID-19 problem could be the best solution overall. In addition to international scientific collaboration, the support of international organizations could help prevent an increase in cases, particularly in countries and regions where COVID-19 is in the early epidemic stage.
  21 in total

Review 1.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

Review 2.  Virtual Learning During the COVID-19 Pandemic: A Bibliometric Review and Future Research Agenda.

Authors:  Eglantina Hysa; Ahsan Akbar; Fakhra Yasmin; Atteeq Ur Rahman; Shengbing Li
Journal:  Risk Manag Healthc Policy       Date:  2022-07-17

Review 3.  Biosensing surfaces and therapeutic biomaterials for the central nervous system in COVID-19.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  Emergent Mater       Date:  2021-03-10

4.  Quantity does not equal quality: Scientific principles cannot be sacrificed.

Authors:  Piotr Rzymski; Michał Nowicki; Gerard E Mullin; Ajith Abraham; Eduardo Rodríguez-Román; Moritz B Petzold; Antonia Bendau; Kamal Kant Sahu; Amber Ather; Anne-Frédérique Naviaux; Pascal Janne; Maximilien Gourdin; Joris R Delanghe; Hans D Ochs; James E Talmadge; Manish Garg; Michael R Hamblin; Nima Rezaei
Journal:  Int Immunopharmacol       Date:  2020-06-22       Impact factor: 4.932

Review 5.  The urgent need for integrated science to fight COVID-19 pandemic and beyond.

Authors:  Negar Moradian; Hans D Ochs; Constantine Sedikies; Michael R Hamblin; Carlos A Camargo; J Alfredo Martinez; Jacob D Biamonte; Mohammad Abdollahi; Pedro J Torres; Juan J Nieto; Shuji Ogino; John F Seymour; Ajith Abraham; Valentina Cauda; Sudhir Gupta; Seeram Ramakrishna; Frank W Sellke; Armin Sorooshian; A Wallace Hayes; Maria Martinez-Urbistondo; Manoj Gupta; Leila Azadbakht; Ahmad Esmaillzadeh; Roya Kelishadi; Alireza Esteghamati; Zahra Emam-Djomeh; Reza Majdzadeh; Partha Palit; Hamid Badali; Idupulapati Rao; Ali Akbar Saboury; L Jagan Mohan Rao; Hamid Ahmadieh; Ali Montazeri; Gian Paolo Fadini; Daniel Pauly; Sabu Thomas; Ali A Moosavi-Movahed; Asghar Aghamohammadi; Mehrdad Behmanesh; Vafa Rahimi-Movaghar; Saeid Ghavami; Roxana Mehran; Lucina Q Uddin; Matthias Von Herrath; Bahram Mobasher; Nima Rezaei
Journal:  J Transl Med       Date:  2020-05-19       Impact factor: 5.531

Review 6.  Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.

Authors:  Kawthar Mohamed; Niloufar Yazdanpanah; Amene Saghazadeh; Nima Rezaei
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

7.  Emerging Standards and the Hybrid Model for Organizing Scientific Events During and After the COVID-19 Pandemic.

Authors:  Sara Hanaei; Amirhossein Takian; Reza Majdzadeh; Christopher Ryan Maboloc; Igor Grossmann; Orlando Gomes; Milos Milosevic; Manoj Gupta; Alireza A Shamshirsaz; Amine Harbi; Amer M Burhan; Lucina Q Uddin; Arutha Kulasinghe; Chi-Ming Lam; Seeram Ramakrishna; Abass Alavi; Jan L Nouwen; Tommaso Dorigo; Michael Schreiber; Ajith Abraham; Natalya Shelkovaya; Wojtek Krysztofiak; Majid Ebrahimi Warkiani; Frank Sellke; Shuji Ogino; Francisco J Barba; Serge Brand; Clara Vasconcelos; Deepak B Salunke; Nima Rezaei
Journal:  Disaster Med Public Health Prep       Date:  2020-10-26       Impact factor: 1.385

8.  The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.

Authors:  Amir Hossein Mansourabadi; Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Life Sci       Date:  2020-08-01       Impact factor: 5.037

Review 9.  Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.

Authors:  Arefeh Basiri; Zahra Pazhouhnia; Nima Beheshtizadeh; Mahdieh Hoseinpour; Amene Saghazadeh; Nima Rezaei
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 5.739

Review 10.  Microfluidic devices for detection of RNA viruses.

Authors:  Arefeh Basiri; Arash Heidari; Melina Farshbaf Nadi; Mohammad Taha Pahlevan Fallahy; Sasan Salehi Nezamabadi; Mohammadreza Sedighi; Amene Saghazadeh; Nima Rezaei
Journal:  Rev Med Virol       Date:  2020-08-26       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.